Background and Purpose—Exposure to vascular risk factors has a gradual deleterious effect on brain MRI and cognitive measures. We explored whether a pattern of these measures exists that predicts stroke and Alzheimer disease (AD) risk.

Methods—A cognitive battery was administered to 1679 dementia and stroke-free Framingham offspring (age, >55 years; mean, 65.7±7.0) between 1999 and 2004; participants were also free of other neurological conditions that could affect cognition and >90% also had brain MRI examination. We related cognitive and MRI measures to risks of incident stroke and AD ≤10 years of follow-up. As a secondary analysis, we explored these associations in The Framingham Heart Study original cohort (mean age, 67.5±7.3 and 84.8±3.3 years at the cognitive assessment and MRI examination, respectively).

Results—A total of 55 Offspring participants sustained strokes and 31 developed AD. Offspring who scored <1.5 SD below predicted mean scores, for age and education, on an executive function test, had a higher risk of future stroke (hazard ratio [HR], 2.27; 95% confidence interval [CI], 1.06–4.85) and AD (HR, 3.60; 95% CI, 1.52–8.52); additional cognitive tests also predicted AD. Participants with low (<20 percentile) total brain volume and high (>20 percentile) white matter hyperintensity volume had a higher risk of stroke (HR, 1.97; 95% CI, 1.03–3.77 and HR, 2.74; 95% CI, 1.51–5.00, respectively) but not AD. Hippocampal volume at the bottom quintile predicted AD in the offspring and original cohorts (HR, 4.41; 95% CI, 2.00–9.72 and HR, 2.37; 95% CI, 1.12–5.00, respectively). A stepwise increase in stroke risk was apparent with increasing numbers of these cognitive and imaging markers.

Conclusions—Specific patterns of cognitive and brain structural measures observed even in early aging predict stroke risk and may serve as biomarkers for risk prediction. (Stroke. 2013;44:2787-2794.)

Key Words: Alzheimer disease ■ cognition ■ magnetic resonance imaging ■ stroke
exclusion of participants with prevalent stroke or dementia, and those with neurological conditions that could affect their cognition, with incomplete follow-up or education information and people aged <55 years, 1679 people aged >55 years were available for cognitive analysis, and among them, 1469 also had brain MRI measures.

A cognitive test battery was administered to the original cohort participants between 1976 and 1978; most of these tests were included in the subsequently designed offspring battery. Of the participants who were tested (n=2123), 1456 were native English speakers, had complete follow-up information, and did not have prevalent stroke or dementia, meeting an inclusion criteria for the cognitive analyses. Approximately 23 years later, surviving participants from the original cohort were invited to undergo brain MRI. Among the 478 alive in 2005, 266 participants had MRI information, and after excluding individuals with prevalent stroke or dementia or with neurological conditions that might confound the assessment of cognitive function and structural brain measurement, 224 people were available for these MRI analyses.

Prosp ective surveillance for incident stroke and AD is ongoing and for these analyses data were used for the period extending 10 years from the date of the MRI and cognitive testing or until December 2009, whichever occurred earlier.

Data were obtained under a protocol approved by the Institutional Review Board of the Boston University Medical Center and informed consent was obtained from all participants.

**Methodology for Volumetric Brain MRI**

Participants were evaluated with a 1 or 1.5-Tesla Siemens Magnetom scanner. Three-dimensional (3D) T1 and double echo proton density and T2 coronal images acquired in 4-mm contiguous slices were performed. All images were transferred to the centralized reading center at the University of California—Davis Medical Center and analyses were performed on QUANTA 6.2, a custom-designed image analysis package. All images were read centrally, blind to the subject’s identity, age, sex, exposure to stroke risk factors, and cognitive performance on cognitive testing. Total cerebral brain volume (TCBV), hippocampal volume (HPV), and white matter hyperintensity volume (WMHV) assessments, as well as their inter-rater reliability, have been described previously.22–26 Brain volume calculation was performed using semiautomated analysis of pixel distributions on the basis of mathematical modeling of MRI pixel intensity histograms for cerebrospinal fluid and brain matter (white matter and gray matter) to determine the optimal threshold of pixel intensity to best distinguish cerebrospinal fluid from brain matter. TCBV was computed as the ratio of total brain parenchymal volume to total cranial volume to correct for differences in head size.

WMHV was expressed as a proportion of total cranial volume to correct for head size and was log transformed for all regression analyses. HPV was measured as the sum of right and left hippocampal volumes assessed using in-house software that allowed for 3D visualization at x3 magnification of the image. Areas included were the CA1–CA4 fields, dentate gyrus, and the subicular complex. On a coronal 3D MRI data set resliced to be aligned perpendicular to the long axis of the hippocampus, borders were traced on contiguous 1.5-mm coronal slices, and these slice-specific volumes were summed to give hippocampal volume for each side.

Finally, the presence or the absence of silent cerebral infarcts (SCIs) was determined manually by the operator, on the basis of size (≥3 mm), location, and imaging characteristics of the lesion.

**Cognitive Tests**

Subjects were administered a cognitive test battery using standard administration protocols and trained examiners. Description of the tests administered and the cohorts in which they were administered to are presented in Table 1. Additional details of tests administered and normative values for the FHS original23 and offspring20 cohorts have been published. The cognitive test battery administered between 1999 and 2004 to the offspring cohort and the battery administered previously to the original cohort both included the following tests: logical memory, visual memory, paired associate, immediate recall, and similarities. The offspring’s cognitive battery also included: Hooper Visual Organization Test, Trail Making Test A, Trail Making Test B (TrB), and Boston Naming Test, and the original cohort battery included the following tests in addition: Digit Span Forward, Digit Span Backward, and Controlled Word Association Fluency Test. Hooper Visual Organization Test, Boston Naming Test, Trail Making Test A, and TrB were log transformed to normalize for skewed distribution.

**Figure 1. Flow diagram of study participants.**

Outcomes

All participants of the FHS are under continuous surveillance for stroke and impairment in cognitive function. We have previously outlined our screening and surveillance methods for the development of stroke or dementia. In brief, stroke was defined as an acute-onset focal neurological deficit of presumed vascular pathogenesis lasting more than 24 hours. All stroke subtypes were included in the analyses. Ischemic stroke was diagnosed if a focal neurological deficit was documented, imaging showed an infarct that correlated with the clinical deficit, or an infarct was documented at autopsy. Hemorrhagic stroke was defined on the basis of brain imaging, lumbar puncture, or autopsy.

AD was diagnosed on the basis of criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) for definite, probable, or possible AD.

Statistical Analysis

We used multivariable Cox regression to examine the associations of MRI and cognitive measures with incident stroke and AD among the offspring cohort. Independent variables were defined as continuous or dichotomous. To allow comparisons between performance in different cognitive tests and between different regional brain volumes, we used continuous variables transformed using standardized residuals (Z scores) from cohort-specific regressions onto age (and education for the cognitive outcomes). Cognitive measures were dichotomized with a cutoff set at Z ≥−1.5 and cognitive deficit in a specific domain was defined as a Z score below that cutoff. The cutoff of 1.5 SD below the mean is in accordance with previous studies. Brain MRI measures were divided into cohort-specific quintiles, and the most abnormal quintile (for TCBV and HPV this is the bottom quintile and for WMHV the top quintile) was compared with the rest. The models were adjusted for age and sex and in a subsequent model additionally for hypertension, smoking, prevalent diabetes mellitus, body mass index, and ApoE4 genotype status. In secondary analyses, we examined these associations in the original cohort. ApoE4 genotype information was not available as a covariate in all people in the offspring cohort. We ran sensitivity analyses using only the outcomes of probable AD.

We ran Cox-proportional hazards models relating the number of identified predictor variables for stroke to risk of subsequent stroke and AD and illustrate these using cumulative hazard function.

Finally, we estimated net reclassification improvement, using continuous Cox-proportional hazards–based models, observed on adding each of the statistically significant predictors of stroke risk in a stepwise regression model to the Framingham stroke risk profile (FSRP). The FSRP provides an estimate of the 10-year risk of stroke for a given individual based on age, sex, and measurements of systolic blood pressure, antihypertensive therapy, diabetes mellitus, smoking status, history of cardiovascular disease, and the presence of atrial fibrillation or the left ventricular hypertrophy on the ECG. It has been previously described and validated for stroke prediction risk both at Framingham and in other populations. Analyses were performed using Statistical Analyses System software version 9.2 (SAS Institute, Cary, NC).

Results

The baseline characteristics of study participants from the offspring cohort and the original cohort (both at the time of the cognitive assessment and at the MRI examination) are presented in Table 2. The mean age of the offspring was 65.7±7.0 years. The mean ages of the original cohort at the cognitive assessment and at the later MRI examination were 67.5±7.3 and 84.8±3.3 years, respectively. The mean duration of follow-up for stroke was 7.4±1.7 years for the offspring cohort, 8.7±2.5 years for the original cohort, and 5.9±2.3 for the original cohort survivors who underwent MRI (Figure 1).

Predictors of Stroke

Cognitive Measures

Among the offspring, 55 of 1679 developed a stroke. Poorer performance on TrB, a measure of executive function, was associated with a higher risk of stroke (hazard ratio [HR], 1.27; 95% confidence interval [CI], 1.01–1.59), and this association did not attenuate after additional adjustments (Table 3). The risk of future stroke more than doubled in individuals whose executive function performance fell below a predefined threshold (using TrB; cognitive Z scores less than −1.5) compared with those with intact executive function (HR, 2.27; 95% CI, 1.06–4.85), even after adjustment for concomitant levels of vascular risk factors (HR, 2.25; 95% CI, 1.05–4.86; Table 4). Seventeen percent of people with poor performance on TrB and 12% of people with better performance had SCI (P=0.200). Adjustment for SCI also did not

Table 1. Description of the Neuropsychological Tests

<table>
<thead>
<tr>
<th>Neuropsychological Tests</th>
<th>Cohort in Which Test Was Administered</th>
<th>Cognitive Domain Assessed</th>
<th>Origin of Test</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>LM</td>
<td>Original and offspring</td>
<td>Verbal memory—delayed recall</td>
<td>WMS</td>
<td>0–24</td>
</tr>
<tr>
<td>PAS</td>
<td>Original and offspring</td>
<td>Verbal learning</td>
<td>WMS</td>
<td>0–21</td>
</tr>
<tr>
<td>VR</td>
<td>Original and offspring</td>
<td>Visual memory—immediate recall</td>
<td>WMS</td>
<td>0–14</td>
</tr>
<tr>
<td>HVOT</td>
<td>Offspring</td>
<td>Visuoperception</td>
<td>...</td>
<td>30</td>
</tr>
<tr>
<td>SIM</td>
<td>Original and offspring</td>
<td>Abstract reasoning</td>
<td>WAIS</td>
<td>0–26</td>
</tr>
<tr>
<td>DSF</td>
<td>Original</td>
<td>Short-term memory capacity</td>
<td>WAIS</td>
<td>0–9</td>
</tr>
<tr>
<td>DSB</td>
<td>Original</td>
<td>Executive function</td>
<td>WAIS</td>
<td>0–8</td>
</tr>
<tr>
<td>COWAT</td>
<td>Original</td>
<td>Perceptuo-motor speed</td>
<td>Halstead-Reitan</td>
<td>0–420 (time to completion in seconds)</td>
</tr>
<tr>
<td>TrA</td>
<td>Offspring</td>
<td>Executive function</td>
<td>Halstead-Reitan</td>
<td>0–600 (time to completion in seconds)</td>
</tr>
<tr>
<td>TrB</td>
<td>Offspring</td>
<td>Language</td>
<td>...</td>
<td>30</td>
</tr>
</tbody>
</table>

BNT indicates Boston Naming Test; COWAT, Controlled Word Association Test; DFS, Digit Span Backward; DSF, Digit Span Forward; HVOT, Hooper Visual Organization Test; LM, logical memory; PAS, paired associates; SIM, Similarities test; TrA, Trail Making Test A; TrB, Trail Making Test B; VR, visual reproductions; WAIS, Wechsler Adult Intelligence Scale; and WMS, Wechsler Memory Scale.
Table 2. Baseline Characteristics of Study Participants From the Offspring and Original Cohorts

<table>
<thead>
<tr>
<th></th>
<th>Offspring Cohort</th>
<th>Cognitive Assessment</th>
<th>MRI Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>1679</td>
<td>1456</td>
<td>224</td>
</tr>
<tr>
<td>Age, y</td>
<td>65.7±7.0</td>
<td>67.5±7.3</td>
<td>84.8±3.3</td>
</tr>
<tr>
<td>Women</td>
<td>895 (53.3)</td>
<td>869 (59.7)</td>
<td>139 (62.0)</td>
</tr>
<tr>
<td>High school graduate</td>
<td>1606 (95.7)</td>
<td>1042 (72)</td>
<td>187 (83.5)</td>
</tr>
<tr>
<td>Hypertension*</td>
<td>806 (48.8)</td>
<td>768 (52.8)</td>
<td>185 (76.8)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>28.2±5.2</td>
<td>27.1±4.5</td>
<td>27.2±4.4</td>
</tr>
<tr>
<td>Current smokers</td>
<td>166 (10.1)</td>
<td>363 (25.6)</td>
<td>7 (3.5)</td>
</tr>
<tr>
<td>Diabetes mellitus†</td>
<td>211 (13.2)</td>
<td>108 (8.1)</td>
<td>26 (14.7)</td>
</tr>
<tr>
<td>ApoE ε</td>
<td>367 (22.5)</td>
<td>…</td>
<td>46 (20.6)</td>
</tr>
</tbody>
</table>

Values are n (%) or mean±SD.

*Hypertension was defined as either systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or the use of antihypertensive medication.

†Diabetes mellitus as a recorded random blood glucose level ≥200 mg/dL (11.1 mmol/L), a previous diagnosis of diabetes mellitus, or the use of insulin or a hypoglycemic agent.

attenuate the strength of the association (HR, 2.28; 95% CI, 0.96–5.39); however, the association was no longer significant, possibly because of lack of statistical power since information on SCI was available only on 86% of the study sample. In the original cohort, 95 of 1445 people sustained a clinical stroke during the follow-up period. As in the offspring, a test measuring executive function (Controlled Word Association Fluency Test) was associated with risk of stroke (HR, 1.28; 95% CI, 1.03–1.58), although this association attenuated after additional adjustments (Table I in the online-only Data Supplement).

Magnetic Resonance Imaging Measures

Among the 1469 participants from the offspring cohort who had brain MRI measures, 45 were diagnosed with stroke during the follow-up period. Each 1 SD decrease in TCBV, and increase in WMHV, was associated with a statistically significant higher risk of incident stroke (HR, 1.61; 95% CI, 1.21–2.13 and HR, 1.42; 95% CI, 1.10–1.83, respectively; Table 3, model A). The association with TCBV but not with WMHV was slightly attenuated by adjusting for vascular risk factors (Table 3, model B). Using the threshold models, we had similar findings with the bottom quintile of TCBV and the top quintile of WMHV being associated with a higher risk of incident stroke (HR, 1.97; 95% CI, 1.03–3.77 and HR, 2.74; 95% CI, 1.51–5.00, respectively; Table 4, model A); however, the association with TCBV was no longer significant after additional adjustments for potential risk factors (Table 4, model B). Although TCBV was not significantly associated with the presence of SCI (15% versus 12% for top TCBV quintile compared with others; P=0.150), people who had WMHV at the top quintile also had more SCI compared with those with lower WMHV (22% versus 10%; P<0.001). The associations of both TCBV and WMHV with incident stroke attenuated after adjustment for SCI; however, the association of WMHV (HR, 2.41; 95% CI, 1.30–4.54) but not TCBV (HR, 1.85; 95% CI, 0.96–3.57) remained statistically significant. Of the 224 older original cohort participants who had MRI measures, 29 sustained a stroke during the follow-up. None of the MRI measures were associated with future stroke in the original cohort (Tables I and II in the online-only Data Supplement).

Predictors of AD

Cognitive Measures

Thirty-two of 1679 offspring participants developed AD (all were probable AD). Performance in all cognitive domains, except visual perception (Hooper Visual Organization Test) was significantly associated with a higher risk of developing AD. The most pronounced associations were between verbal and visual memory and AD (HR, 2.75; 95% CI, 1.95–3.90 and HR, 2.58; 95% CI, 1.76–3.79, respectively; Table 3, model A). Most associations remained significant and robust after controlling for risk factors, although the association with paired associate was no longer significant (Table 3, model B). In the threshold model, impairment in logical memory, visual memory, Trail Making Test A, and TrB were associated with incident AD.

Of the 1445 participants from the original cohort, 72 were classified as having at least mild AD during the follow-up (7 were possible AD, 3 of whom had a clinical stroke, and the rest were probable AD). The findings here were comparable with those in the offspring cohort. Of the tests which were administered only in this sample, a measure of executive function (Controlled Word Association Fluency Test) was associated with AD (HR, 1.47; 95% CI, 1.12–1.92); however, the association was not significant after additional adjustments or when a threshold model was applied. In addition, another test that measures executive function, Digit Span Backward, was not associated with AD (Tables I and II in the online-only Data Supplement).

Magnetic Resonance Imaging Measures

During the follow-up period, 28 of 1469 offspring participants who underwent MRI developed AD (all were probable AD). Lower HPV predicted increased risk of AD (Tables 2 and 4), with >4× the risk of AD for those at the bottom HPV quintile (Table 4). The association with continuous HPV attenuated after additional adjustment for vascular risk factors and ApoE ε4 genotype (Table 3), but remained significant in the threshold model (Table 4).

Thirty-seven participants of the original cohort of 224 people who underwent brain MRI (22% of the original cohort participants who survived until 1999 when the MRI evaluations began) were diagnosed with AD (2 were possible AD, none of whom had a clinical stroke and the rest were probable AD). In this sample of elderly people, HPV predicted future AD as in the offspring; however, in addition, low TCBV was a strong predictor of AD (HR, 6.69; 95% CI, 2.62–17.09; Tables I and II in the online-only Data Supplement). The results were similar when we used probable AD as an outcome rather than possible AD in the original cohort.

Overall Patterns

The age-adjusted bivariate intercorrelations were 0.063, 0.047, and 0.019 for the following pairs of stroke-associated...
indicator variables, respectively: TCBV and TrB, WMHV and TrB, and TCBV and WMHV. There was a dose-dependent relationship between the number of these 3 stroke predictors and the risk of developing stroke (*P* < 0.001), but not AD (Figure 2).

The net reclassification improvement on adding WMHV to the FSRP was estimated at 0.37 and was statistically significant (95% CI, 0.02, 0.85). The net reclassification improvement on adding TCBV or TrB to the FSRP was not statistically significant.

### Discussion

Our findings demonstrate a specific pattern of cognitive deficits and brain MRI measures that precede the occurrence of stroke. Hence, we suggest that vascular risk factors may have a continuous subclinical deleterious effect on the brain, which in turn may manifest as a clinical stroke. Individuals with a deficit in executive function, with low total brain volume or large white matter hyperintensity volumes, had twice or more the risk of future stroke, and having more of these markers was associated with a gradual increase in stroke risk. This pattern was specific to stroke and was not demonstrated in AD.

Previous literature has suggested that people with cognitive impairment may have a higher risk of subsequent stroke, independently of vascular risk factors, and emphasized the role of cerebrovascular disease in cognitive impairment. Our finding that in both the offspring and the original cohorts measures of executive function were associated with incident stroke is reasonable considering that these measures reflect the integrity of the frontal lobe which is more prone to subclinical vascular injury. However only TrB, a measure of executive function, predicted stroke independently of vascular risk factors. This is in accordance with another study that demonstrated an independent association of TrB (and not Trail Making Test A or the Mini Mental State Examination) to subsequent risk of brain infarction in a sample of 930 elderly men followed for 13 years. The presence of SCI could not explain, in our analysis, the association between TrB and risk of incident stroke.

Although TrB also predicted AD, total brain volume and white matter hyperintensity volume were specific for stroke...
We and others have previously shown that white matter hyperintensity volume is related to risk of incident stroke; however, to our knowledge, we are demonstrating for the first time an association between total brain volume and risk of incident stroke. Unlike white matter hyperintensity volume, which was an independent predictor, the association of total brain volume with risk of stroke attenuated after controlling for vascular risk factors, and in the threshold model was no longer significant. Moreover, white matter hyperintensity volume significantly improved the predictive value compared with the

### Table 4. Hazard Ratios (95% CI) for Stroke and AD Associated With Cognitive Deficit (Z Score of Cognitive Measure, ≤1.5) and With Quintiles of MRI Measures (Bottom vs Others for TCBV and HPV and Top vs Others for WMHV) Among the Offspring Cohort

<table>
<thead>
<tr>
<th>Cognitive tests</th>
<th>Model A*</th>
<th></th>
<th></th>
<th>Model B†</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TCBV</td>
<td>1.97 (1.03–3.77)</td>
<td>0.040</td>
<td>1.57 (0.61–4.04)</td>
<td>1.78 (0.92–3.45)</td>
<td>1.47 (0.54–4.04)</td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>0.90 (0.42–1.94)</td>
<td>&lt;0.001</td>
<td>4.41 (2.00–9.72)</td>
<td>0.89 (0.41–1.93)</td>
<td>3.53 (1.53–8.13)</td>
<td></td>
</tr>
<tr>
<td>WMHV§</td>
<td>2.74 (1.51–5.00)</td>
<td>0.001</td>
<td>1.36 (0.60–3.10)</td>
<td>2.73 (1.48–5.02)</td>
<td>1.43 (0.61–3.36)</td>
<td></td>
</tr>
</tbody>
</table>

AD indicates Alzheimer disease; BNT, Boston Naming Test; CI, confidence interval; HPV, hippocampal volume; HVOT, Hooper Visual Organization Test; LM, logical memory; PAS, paired associates; SIM, Similarities test; TCBV, total cerebral brain volume; TRa, Trail Making Test A; TRb, Trail Making Test B; VR, visual reproductions; and WMHV, white matter hyperintensity volume.

*Model A: adjusted for age and sex.
†Model B: adjusted for age, sex, education, hypertension, current smoking, history of diabetes mellitus, body mass index, and ApoEε4 status.
‡Variables are log-transformed.

Figure 2. Cumulative incidence of stroke (left) and Alzheimer disease (AD; right) in the offspring cohort based on age- and sex-adjusted Cox models by number of indicators among: poor performance on Trail making B test, top WMHV quintile and bottom TCBV quintile.
Weinstein et al

MRI and Cognitive Predictors of Stroke and AD

FSRP, a finding that is supported by a recent study, whereas total brain volume did not. Therefore, we conclude that total brain volume reflects current vascular burden, whereas white matter hyperintensity volume may represent cumulative vascular risk or, albeit less likely, a distinct, nonvascular mechanism. Keeping this in mind, the fact that total brain volume was related to risk of stroke in the younger offspring sample and to risk of AD in the elderly survivors from the original cohort is plausible because vascular burden is associated with both conditions but AD occurs later in life and the changes preceding it might be delayed until the eighth and subsequent decades.

Similarly, the absence of associations between any brain MRI measure and risk of incident stroke among the survivors of the original cohort may be explained by a healthy survivor bias. Prior studies have also demonstrated a negative association between total brain volume and vascular burden as assessed by the FSRP. Moreover, presence and progression of lacunar infarcts, as well as white matter hyperintensity volume, were shown to be associated with a greater decrease in total brain volume. In the present analysis, the associations of both total cerebral brain volume and white matter hyperintensity volume with incident stroke could be only partially explained by the concomitant presence of SCIs.

Previous studies have demonstrated the existence of a long preclinical phase for AD, which involves impairment in multiple cognitive domains, as well as changes in brain MRI measures. Accordingly, in the current study, multiple tests, such as verbal and visual memory, abstract reasoning and language, were predictive of AD risk. Interestingly, measures of executive function (TrB) in the offspring but not in the original cohort (DFB, Controlled Word Association Fluency Test) strongly predicted the risk of incident AD. This finding is especially intriguing considering the fact that all cases of AD in the offspring were classified as probable AD and thus the association between TrB and AD was less likely to be driven by cases of mixed AD and vascular pathology. Inconsistency about the ability of measures of executive function to predict AD exists also in the literature and may be because of differences in tests (Digit span test is less demanding than Trail making), in sample characteristics, or because of different time courses between the baseline assessment and onset of clinical dementia. Our study demonstrates a strong association between hippocampal volume and future AD risk which is in line with prior studies; however, our observation that low hippocampal volume is related to AD risk more strongly among those at late middle-age as compared with the elderly (bottom quintile of hippocampal volume confers 4x the risk in the offspring compared with a doubling of the risk in the original cohort) is intriguing and needs further exploration.

The strengths of this study are its large sample and its prospective, population-based design, with a comprehensive cognitive battery and volumetric MRI measures at baseline, and a careful surveillance for clinical outcomes. The fact that the same methods and surveillance were applied to multiple generations enabled us to compare the 2 samples which were, for the MRI measures, also of different ages. Also, compared with previous publications, this study included a younger sample with a mean age of only 66 years. Limitations include the potential for healthy survivor bias among participants from the original cohort who underwent MRI and the predominantly European origin and highly educated status of our samples that limits the study generalizability.

Stroke often occurs without prior warning, and when clinical symptoms appear, it is often too late for an effective treatment. Thus, it is of great importance to define biomarkers for early detection of people who are at a higher risk. These biomarkers can then help identify candidates who would benefit maximally from preventive interventions, help define end points for clinical trials and endophenotypes for genetic studies, and contribute to the creation of a composite risk score for stroke. Future studies are warranted to validate these markers, to study the time points in one’s lifespan at which they would be most useful and to integrate these with other demographic, circulating and imaging biomarkers, both established and novel, to improve risk prediction.

Sources of Funding

This work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung and Blood Institute’s Framingham Heart Study (Contract No. N01-HC-25195) and by grants from the National Institute of Neurological Disorders and Stroke (NS17950), the National Heart, Lung and Blood Association (HL93029, U01HL 096917) and the National Institute of Aging (AG08122, AG16495, AG03193, AG031287, P30AG013846). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Heart Lung and Blood Institute, the National Institute of Aging or the National Institutes of Health.

Disclosures

None.

References


Brain Imaging and Cognitive Predictors of Stroke and Alzheimer Disease in the Framingham Heart Study
Galit Weinstein, Alexa S. Beiser, Charles DeCarli, Rhoda Au, Philip A. Wolf and Sudha Seshadri

Stroke. 2013;44:2787-2794; originally published online August 6, 2013;
doi: 10.1161/STROKEAHA.113.000947

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/44/10/2787

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2013/08/06/STROKEAHA.113.000947.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/
Brain Imaging and Cognitive Predictors of Stroke and Alzheimer Disease in the Framingham Heart Study

Galit Weinstein, PhD, Alexa S. Beiser, PhD, Charles DeCarli, MD, Rhoda Au, PhD, Philip A. Wolf, MD, Sudha Seshadri, MD.

SUPPLEMENTAL MATERIAL
### Supplementary table I: Hazard Ratios (95% CI) for stroke and AD associated with 1SD decrease in cognitive/MRI measure among the Original cohort

<table>
<thead>
<tr>
<th>Cognitive tests</th>
<th>Model A*</th>
<th>Model B†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incident stroke</td>
<td>Incident AD</td>
</tr>
<tr>
<td>No. of events /max sample size</td>
<td>95/1,445</td>
<td>72/1,445</td>
</tr>
<tr>
<td>LM</td>
<td>1.12 (0.91-1.38)</td>
<td>1.92 (1.44-2.57)</td>
</tr>
<tr>
<td>PAS</td>
<td>1.03 (0.84-1.27)</td>
<td>1.73 (1.36-2.18)</td>
</tr>
<tr>
<td>VR</td>
<td>0.98 (0.80-1.20)</td>
<td>1.44 (1.10-1.88)</td>
</tr>
<tr>
<td>SIM</td>
<td>1.11 (0.91-1.35)</td>
<td>1.61 (1.28-2.02)</td>
</tr>
<tr>
<td>DSF</td>
<td>1.31 (1.09-1.57)</td>
<td>0.89 (0.71-1.12)</td>
</tr>
<tr>
<td>DSB</td>
<td>1.12 (0.91-1.38)</td>
<td>0.88 (0.70-1.11)</td>
</tr>
<tr>
<td>COWAT</td>
<td>1.28 (1.03-1.58)</td>
<td>1.47 (1.12-1.92)</td>
</tr>
<tr>
<td>No. of events /max sample size</td>
<td>29/224</td>
<td>37/224</td>
</tr>
<tr>
<td>MRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCBV</td>
<td>0.97 (0.64-1.46)</td>
<td>2.40 (1.63-3.55)</td>
</tr>
<tr>
<td>HPV</td>
<td>0.83 (0.57-1.23)</td>
<td>1.88 (1.27-2.76)</td>
</tr>
<tr>
<td>WMHV‡</td>
<td>0.85 (0.58-1.24)</td>
<td>0.90 (0.66-1.25)</td>
</tr>
</tbody>
</table>

CI=Confidence Interval; MRI=Magnetic Resonance Imaging; LM=Logical Memory; PAS=Paired Associates; VR=Visual Reproductions; SIM=Similarities test; DSF=Digit Span Forward; DFB=Digit Span Backward; COWAT=Controlled word association test; TCBV=Total Cerebral Brain Volume; HPV=Hippocampal Volume; WMHV=White Matter Hyperintensity Volume.

*Model A: Adjusted for age and sex
†Model B: Adjusted for age, sex, education, hypertension, current smoking, history of DM, and BMI.
‡HRs are for 1SD increase in this measure
**Supplementary table II:** Hazard Ratios (95% CI) for stroke and AD associated with cognitive deficit (z-score of cognitive measures ≤ 1.5) and with quintiles of MRI measures (bottom vs. others for TCBV and HPV and top vs. others for WMHV) among the Original cohort

<table>
<thead>
<tr>
<th></th>
<th>Cognitve tests</th>
<th>MRI</th>
<th>Model A*</th>
<th>Model B†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incident stroke</td>
<td>Incident AD</td>
<td>Incident stroke</td>
<td>Incident AD</td>
</tr>
<tr>
<td>LM</td>
<td>1.52 (0.66-3.49)</td>
<td><strong>5.66 (2.86-11.20)</strong></td>
<td>1.66 (0.71-3.87)</td>
<td><strong>5.35 (2.38-12.02)</strong></td>
</tr>
<tr>
<td>PAS</td>
<td>0.55 (0.17-1.73)</td>
<td>1.85 (0.85-4.04)</td>
<td>0.63 (0.20-2.02)</td>
<td>1.44 (0.56-3.73)</td>
</tr>
<tr>
<td>VR</td>
<td>1.31 (0.53-3.26)</td>
<td><strong>2.90 (1.03-8.21)</strong></td>
<td>1.48 (0.59-3.69)</td>
<td><strong>3.22 (1.13-9.17)</strong></td>
</tr>
<tr>
<td>SIM</td>
<td>1.44 (0.77-2.71)</td>
<td><strong>2.67 (1.40-5.10)</strong></td>
<td>1.44 (0.72-2.90)</td>
<td>2.11 (0.95-4.71)</td>
</tr>
<tr>
<td>DSF</td>
<td>1.22 (0.56-2.63)</td>
<td>0.66 (0.21-2.10)</td>
<td>1.03 (0.45-2.38)</td>
<td>0.24 (0.03-1.77)</td>
</tr>
<tr>
<td>DSB</td>
<td>0.54 (0.13-2.20)</td>
<td>1.00 (0.25-4.09)</td>
<td>0.67 (0.16-2.77)</td>
<td>1.38 (0.32-5.91)</td>
</tr>
<tr>
<td>COWAT</td>
<td>1.08 (0.44-2.67)</td>
<td>2.28 (0.91-5.70)</td>
<td>1.40 (0.56-3.47)</td>
<td>1.12 (0.27-4.66)</td>
</tr>
<tr>
<td>TCBV</td>
<td>0.78 (0.27-2.28)</td>
<td><strong>5.16 (2.62-10.18)</strong></td>
<td>0.54 (0.13-2.33)</td>
<td><strong>6.69 (2.62-17.09)</strong></td>
</tr>
<tr>
<td>HPV</td>
<td>0.29 (0.07-1.25)</td>
<td><strong>2.37 (1.12-5.00)</strong></td>
<td>0.09 (0.01-0.78)</td>
<td><strong>2.72 (1.13-6.55)</strong></td>
</tr>
<tr>
<td>WMHV</td>
<td>0.64 (0.22-1.86)</td>
<td>0.91 (0.40-2.08)</td>
<td>0.60 (0.15-2.37)</td>
<td>1.13 (0.43-2.95)</td>
</tr>
</tbody>
</table>

MRI= Magnetic Resonance Imaging; LM = Logical Memory; PAS = Paired Associates; VR = Visual Reproductions; SIM = Similarities test; DSF = Digit Span Forward; DFB = Digit Span Backward; COWAT = Controlled word association test; TCBV = Total Cerebral Brain Volume; HPV = Hippocampal Volume; WMHV = White Matter Hyperintensity Volume.

* Model A: Adjusted for age and sex
† Model B: Adjusted for age, sex, education, hypertension, current smoking, history of DM, and BMI.
‡ Numbers are small